The paroxysmal nocturnal hemoglobinuria market is witnessing robust growth, driven by increasing disease awareness, improved diagnostics, and the expanding adoption of targeted therapies. The approval ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan led to greater improvements in hemoglobin compared with eculizumab among patients with paroxysmal ...

These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, multi-system, life-threatening disease, and diagnosing it early in the clinical course is essential for optimizing management ...

Please provide your email address to receive an email when new articles are posted on . Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain ...

Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal ...

Pegcetacoplan is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that inhibits the complement cascade centrally at C3. Apellis Pharmaceuticals announced positive topline ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare immune disease that causes your body to break down red blood cells when it should not. This disorder happens when there is a problem with certain ...

BOSTON, April 5, 2011 (GLOBE NEWSWIRE) -- Oncology Care Live (www.OncologyCarelive.com ), the live online oncology congress, today announced that Michael J. Borowitz ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...

We have recently had the opportunity of studying a case of march hemoglobinuria in a young woman in whom attacks were precipitated by short walks. The present communication describes the clinical and ...